Unknown

Dataset Information

0

Relative vaccine effectiveness against COVID-19 hospitalisation in persons aged ≥ 65 years: results from a VEBIS network, Europe, October 2021 to July 2023.

ABSTRACT: To monitor relative vaccine effectiveness (rVE) against COVID-19-related hospitalisation of the first, second and third COVID-19 booster (vs complete primary vaccination), we performed monthly Cox regression models using retrospective cohorts constructed from electronic health registries in eight European countries, October 2021-July 2023. Within 12 weeks of administration, each booster showed high rVE (≥ 70% for second and third boosters). However, as of July 2023, most of the relative benefit has waned, particularly in persons ≥ 80-years-old, while some protection remained in 65-79-year-olds.

SUBMITTER: Fontan-Vela M 

PROVIDER: S-EPMC10905661 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Relative vaccine effectiveness against COVID-19 hospitalisation in persons aged ≥ 65 years: results from a VEBIS network, Europe, October 2021 to July 2023.

Fontán-Vela Mario M   Kissling Esther E   Nicolay Nathalie N   Braeye Toon T   Van Evercooren Izaak I   Holm Hansen Christian C   Emborg Hanne-Dorthe HD   Fabiani Massimo M   Mateo-Urdiales Alberto A   AlKerwi Ala'a A   Schmitz Susanne S   Castilla Jesús J   Martínez-Baz Iván I   de Gier Brechje B   Hahné Susan S   Meijerink Hinta H   Starrfelt Jostein J   Nunes Baltazar B   Caetano Constantino C   Derrough Tarik T   Nardone Anthony A   Monge Susana S  

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 20240101 1

To monitor relative vaccine effectiveness (rVE) against COVID-19-related hospitalisation of the first, second and third COVID-19 booster (vs complete primary vaccination), we performed monthly Cox regression models using retrospective cohorts constructed from electronic health registries in eight European countries, October 2021-July 2023. Within 12 weeks of administration, each booster showed high rVE (≥ 70% for second and third boosters). However, as of July 2023, most of the relative benefit  ...[more]

Similar Datasets

Unknown Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023-January 2024.
| S-EPMC11325250 | biostudies-literature
Unknown Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022.
| S-EPMC10668256 | biostudies-literature
Unknown Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021.
| S-EPMC10668259 | biostudies-literature
Unknown Influenza vaccine effectiveness in Europe: Results from the 2022-2023 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre study.
| S-EPMC10777262 | biostudies-literature
Unknown COVID-19 vaccine effectiveness against symptomatic infection and hospitalisation in Belgium, July 2021 to May 2022.
| S-EPMC10311948 | biostudies-literature
Unknown Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023.
| S-EPMC10797659 | biostudies-literature
Unknown Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023-January 2024.
| S-EPMC11252666 | biostudies-literature
Unknown Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024.
| S-EPMC11890973 | biostudies-literature
Unknown Effectiveness of a Messenger RNA Vaccine Booster Dose Against Coronavirus Disease 2019 Among US Healthcare Personnel, October 2021-July 2022.
| S-EPMC10549208 | biostudies-literature
Unknown Deaths Associated with Pediatric Hepatitis of Unknown Etiology, United States, October 2021-June 2023.
| S-EPMC10977843 | biostudies-literature